The estimated Net Worth of Jorge Di Martino is at least $1.38 Milión dollars as of 4 January 2024. Mr Martino owns over 12,009 units of Kronos Bio stock worth over $302,605 and over the last 4 years he sold KRON stock worth over $310,181. In addition, he makes $765,105 as Chief Medical Officer & Exec. VP of Clinical Devel. at Kronos Bio.
Sign up
Mr D KRON stock SEC Form 4 insiders trading
Mr has made over 6 trades of the Kronos Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 12,009 units of KRON stock worth $14,171 on 4 January 2024.
The largest trade he's ever made was selling 18,657 units of Kronos Bio stock on 12 December 2022 worth over $33,769. On average, Mr trades about 8,541 units every 75 days since 2020. As of 4 January 2024 he still owns at least 315,246 units of Kronos Bio stock.
You can see the complete history of Mr Martino stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Jorge F. DiMartino M.D., Ph.D. biography
Jorge F. DiMartino M.D., Ph.D. is the Chief Medical Officer & Exec. VP of Clinical Devel. at Kronos Bio.
What is the salary of Mr D?
As the Chief Medical Officer & Exec. VP of Clinical Devel. of Kronos Bio, the total compensation of Mr D at Kronos Bio is $765,105. There are no executives at Kronos Bio getting paid more.
How old is Mr D?
Mr D is 58, he's been the Chief Medical Officer & Exec. VP of Clinical Devel. of Kronos Bio since . There are 4 older and 6 younger executives at Kronos Bio. The oldest executive at Kronos Bio, Inc. is Dr. Norbert W. Bischofberger Ph.D., 65, who is the Pres, CEO & Director.
What's Mr D's mailing address?
Jorge's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Insiders trading at Kronos Bio
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger a Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
What does Kronos Bio do?
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
What does Kronos Bio's logo look like?
Complete history of Mr Martino stock trades at Kronos Bio
Kronos Bio executives and stock owners
Kronos Bio executives and other stock owners filed with the SEC include:
-
Jorge F. DiMartino M.D., Ph.D.,
Chief Medical Officer & Exec. VP of Clinical Devel. -
Dr. Norbert W. Bischofberger Ph.D.,
Pres, CEO & Director -
Dr. Yasir B. Al-Wakeel BCh, BM, MA,
CFO & Head of Corp. Devel. -
Dr. Norbert W. Bischofberger,
Pres, CEO & Director -
David M. Tanen J.D.,
Sec. & Director -
Joshua A. Kazam,
Co-Founder & Director -
Marni Kottle,
Sr. VP of Corp. Communications & Investor Relations -
Dr. Christopher Dinsmore Ph.D.,
Chief Scientific Officer -
Barbara A. Kosacz J.D.,
COO & Gen. Counsel -
Charles Lin Ph.D.,
Sr. VP of Biology -
Dr. Pasit Phiasivongsa Ph.D.,
Sr. VP of Pharmaceutical Devel. -
Stephanie Yao,
Exec. Director of Investor Relations & Corp. Communications -
Dr. Christopher Dinsmore,
Chief Scientific Officer -
Barbara A. Kosacz,
COO & Gen. Counsel -
Dr. Yasir B. Al-Wakeel,
CFO & Head of Corp. Devel. -
Norbert W Bischofberger,
PRESIDENT & CEO -
Barbara Kosacz,
COO & General Counsel -
Yasir B. Al Wakeel,
Chief Financial Officer -
Christopher Dinsmore,
Chief Scientific Officer -
Norbert W. & Inger A. Revoc...,
10% owner -
Arie Belldegrun,
-
Rebecka Belldegrun,
Director -
Jakob Loven,
Director -
John C Martin,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Jorge Di Martino,
Chief Medical Officer & VP -
Backer Marianne De,
Director -
Roshawn A. Blunt,
-
Roger D Dansey,
-
David M Tanen,
-
Joshua A Kazam,
-
Allison Frisbee,
SR VP, CORP OPERATIONS & LEGAL -
Charles Y Lin,
SR VP, RESEARCH & DEVELOPMENT -
Elizabeth A Olek,
SR VP, CLINICAL SCIENCE -
Taiyin Yang,
-
Elena Ridloff,
-
Katherine V Stultz,
-
Deborah Knobelman,
Chief Financial Officer